Skip to main content
Defiance International

Published study records

Study records for Melanotan II

Study records describe published research and its limitations. They do not establish efficacy, safety, or suitability for any use.

Study record counts

411 study records.

0 evidence-verified · 382 citation-verified · 26 identifier-confirmed · 3 citation-only

Listed by tier, then records with a public summary first, then publication year, newest first, undated last.

Verified records by research setting

  • In vitro: 114
  • In vivo/preclinical: 251
  • Review/meta-analysis: 3
  • Other: 0
Filter study recordsReset filters

Filtered results

Study type: In vivo/preclinical · Verification: Citation only

  • 2021

Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice

UNC Libraries · 2021

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vitro · Verification: Citation only

  • 2020

China péptido de suministro de Mt -II 10 mg/vial con la construcción de músculo de la USP Melanotan II una experiencia de laboratorio en energías renovables

2020

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.

Study type: In vivo/preclinical · Verification: Citation only

  • 2020

The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice

UNC Libraries · 2020

Study scale: Not reported in the declared source.

Bibliographic details only

No public summary

No plain-language summary is published in this record. Summary availability is separate from its verification. Consult the cited publication when a public link is available.

Limitations and uncertainty

Not reported in the declared source.

Citation only. This record holds no current confirmation of its identifier at PubMed or Crossref. It is held as a citation, not evidence. No tier is an endorsement, an evidence-strength rating, or independent replication, and none establishes efficacy, safety, or suitability.